Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia
Results
Phase 3
This trial looked at idasanutlin and cytarabine for acute myeloid leukaemia that had come back or become resistant to treatment.
People could join the trial between 2015 and 2020. The team published the results in 2022.
Recruitment start: 31 December 2015
Recruitment end: 13 January 2020
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Steve Knapper
Roche
Last reviewed: 25 Aug 2026
CRUK internal database number: 14271
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
